Trogenix is proud to announce its recognition as Startup of the Year at the 2025 Innovation & Entrepreneurship Awards hosted by Cancer Research Horizons, the innovation arm of Cancer Research UK.
Edinburgh, UK, July 2025 – This accolade acknowledges our mission to transform cancer treatment through our proprietary Odysseus™ platform, which engineers next-generation viral vectors capable of targeting tumours with remarkable specificity. The award highlights the dedication and scientific excellence of our entire team – alongside the unwavering support of our partners, investors and the broader oncology community – as we strive to bring hope to patients where current treatments fall short.
The award celebrates UK-based start-ups that have raised their first funding round within the past two years and are rapidly advancing scientific breakthroughs to deliver new treatments, diagnostics or medical devices for the benefit of cancer patients. It recognises the potential of emerging companies, such as Trogenix, to develop and deliver ground-breaking technologies with real promise for growth and impact in the cancer sector.
Our Odysseus™ platform represents a breakthrough in precision immunotherapy – harnessing Synthetic Super-Enhancers (SSEs) which act as docking stations for transcription factors uniquely expressed in aggressive cancer cells. This enables highly selective and potent gene control with multiple layers of safety, including direct tumour injection for localised delivery and self-limiting control mechanisms.
This award serves as a powerful endorsement of our scientific strategy and progress, bolstering our commitment to advancing TGX‑007 into clinical trials for glioblastoma and expanding our research into additional cancers. With each milestone, we’re one step closer to delivering potentially curative, life‑changing treatments to patients and their families.
We extend our gratitude to Cancer Research Horizons for this honour, and we congratulate fellow innovators driving progress in oncology. Winning this award reinforces our resolve to accelerate development, forge strategic collaborations and continue shaping the future of cancer care together.
